UK – Final NICE guidance issued for Akcea’s Tegsedi

Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage drug, Tegsedi (inotersen).

The Highly Specialised Technologies (HST) Guidance is for the treatment of stage I or II polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

It follows the positive Final Evaluation Document (FED) published last month recommending that patients in England with this rare, inherited, severely debilitating and fatal disease, can access the treatment on the NHS.

The drug is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production, and is the first and only subcutaneous RNA-targeting drug designed to reduce the production of TTR protein…